- Home
- SOGP vs PPBT Comparison
SOGP vs PPBT Comparison
Compare SOGP & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOGP
- PPBT
- Stock Information
- Founded
- SOGP 2010
- PPBT 2010
- Country
- SOGP Singapore
- PPBT Israel
- Employees
- SOGP N/A
- PPBT N/A
- Industry
- SOGP
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- SOGP
- PPBT Health Care
- Exchange
- SOGP NYSE
- PPBT Nasdaq
- Market Cap
- SOGP 6.9M
- PPBT 6.3M
- IPO Year
- SOGP 2020
- PPBT N/A
- Fundamental
- Price
- SOGP $5.98
- PPBT $2.49
- Analyst Decision
- SOGP
- PPBT Strong Buy
- Analyst Count
- SOGP 0
- PPBT 1
- Target Price
- SOGP N/A
- PPBT $33.00
- AVG Volume (30 Days)
- SOGP 1.9M
- PPBT 22.4K
- Earning Date
- SOGP 07-15-2025
- PPBT 08-15-2025
- Dividend Yield
- SOGP N/A
- PPBT N/A
- EPS Growth
- SOGP N/A
- PPBT N/A
- EPS
- SOGP N/A
- PPBT N/A
- Revenue
- SOGP $278,363,908.00
- PPBT N/A
- Revenue This Year
- SOGP $48.88
- PPBT N/A
- Revenue Next Year
- SOGP N/A
- PPBT N/A
- P/E Ratio
- SOGP N/A
- PPBT N/A
- Revenue Growth
- SOGP N/A
- PPBT N/A
- 52 Week Low
- SOGP $1.18
- PPBT $2.00
- 52 Week High
- SOGP $6.20
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- SOGP 77.70
- PPBT 52.01
- Support Level
- SOGP $3.71
- PPBT $2.26
- Resistance Level
- SOGP $6.00
- PPBT $2.50
- Average True Range (ATR)
- SOGP 0.77
- PPBT 0.13
- MACD
- SOGP 0.31
- PPBT 0.00
- Stochastic Oscillator
- SOGP 95.28
- PPBT 58.82
About SOGP SOUND GROUP INC SPON ADS EA REP 200 ORD SHS(POST SPLIT)
Sound Group Inc is a world-wide audio-centric social and entertainment company. It Leverages broad product portfolio and in-house technologies, Sound Group caters to user interest in audio entertainment and social networking. Sound Group nurtures a globally diverse and inclusive team, drawing on talent from various countries and regions world-wide.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.